A Phase 2 interventional study of Teropavimab and Zinlirvimab in HIV-1 Infection, sponsored by Gilead Sciences. Active, not recruiting at 34 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection.
The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.
Participants will be randomized in Treatment Groups 1 and 2 to receive LEN, TAB, and ZAB, with differing doses of TAB and ZAB between the 2 groups and in Treatment Group 3 to continue their baseline oral ART for 52 weeks. Eligible participants in Treatment Groups 1 through 3 will have the option of participating in the study extension phase to receive LEN, TAB and ZAB after completing study follow-up through Week 52.
Treatment Group 2 was removed prior to dosing of all groups during Protocol Amendment 2.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive loading dose of lenacapavir (LEN) 600 mg tablets, orally, on Day 1 and Day 2. They will receive LEN 927 mg subcutaneous (SC) injection along with teropavimab (TAB) 2550 mg intravenous (IV) infusion and zinlirvimab (ZAB) 2550 mg IV infusion on Day 1 and every 26 weeks up to Week 52 in the Randomized Phase. At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL will be given the option to participate in the study extension phase. In the study extension phase, participants will continue to receive their randomized study drugs every 26 weeks.
Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Participants in Stay on Baseline Regimen (SBR) group will continue their baseline oral antiretroviral therapy (ART) up to Week 52. Antiretroviral therapy will include drugs like bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide, administered as per standard of care. At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL and in the absence of confirmed virologic rebound throughout the Randomized Phase of the study will switch from oral ART to LEN, TAB and ZAB, every 26 weeks. The participants will switch to receive LEN, TAB, and ZAB every 26 weeks beginning at Week 52.
Drug: Antiretroviral Therapy
At Week 52, participants in this group with HIV-1 RNA \< 50 copies/mL will be given the option to participate in the study extension phase. In the study extension phase, participants will receive LEN 927 mg SC, TAB 2550 mg IV infusion and ZAB 2550 mg IV infusion.
Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Injection
At Week 52, participants in this group will be given the option to participate in the Extension Phase to switch from oral ART to LEN 927 mg SC, TAB 2550 mg IV infusion and ZAB 2550 mg IV infusion, every 26 weeks at the dose specified for Treatment Group 1.
Drug: Teropavimab · Drug: Zinlirvimab · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Administered intravenously
Also known as: GS-5423, 3BNC117-LS
Administered intravenously
Also known as: GS-2872, 10-1074-LS
Administered orally
Also known as: GS-6207
Administered subcutaneously
Also known as: GS-6207, Sunlenca®
Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.
Time frame: Week 26
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm
Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 52 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 52 analysis window and i) discontinued study drug prior to or in the Week 52 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 52 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 52 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.
Time frame: Week 52
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm
Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.
Time frame: Week 26
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm
Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 52 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.
Time frame: Week 52
Change From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 26
Time frame: Baseline, Week 26
Change From Baseline in CD4+ T-cell Counts at Week 52
Time frame: Baseline, Week 52
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 6 years
Trough Concentration at Week 26 Predose for TAB and ZAB
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
Time frame: Week 26 predose
Trough Concentration at Week 26 Predose for LEN
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
Time frame: Week 26 predose
Trough Concentration at Week 52 Predose for TAB and ZAB
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
Time frame: Week 52 predose
Trough Concentration at Week 52 Predose for LEN
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
Time frame: Week 52 predose
Pharmacokinetic (PK) Parameter: AUC0-tau for TAB and ZAB
AUC0-tau is defined as the partial area under the concentration versus time curve from time "0" to time "t".
Time frame: Up to approximately 6 years
PK Parameter: t1/2 for TAB and ZAB
t1/2 is defined as the terminal elimination half-life.
Time frame: Up to approximately 6 years
PK Parameter: Cmax for TAB and ZAB
Cmax is defined as the maximum observed concentration of drug.
Time frame: Up to approximately 6 years
PK Parameter: Cmax for LEN
Cmax is defined as the maximum observed concentration of drug.
Time frame: Up to approximately 6 years
PK Parameter: Tmax for TAB, ZAB, and LEN
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Up to approximately 6 years
Percentage of Participants With Treatment-emergent Anti-TAB and Anti-ZAB Antibodies
Anti-TAB and anti-ZAB antibodies incidence referred to the percentage of participants who have treatment-emergent anti-TAB and anti-ZAB antibodies among all participants evaluable for anti-drug antibody (ADA) incidence.
Time frame: Up to approximately 6 years
241 participants were screened. The study planned to enroll participants in Treatment Groups 1, 2 and 3. However, per review of the programmatic data overall and from study GS-US-536-5816 (NCT04811040), Treatment Group 2 was removed prior to dosing of all groups in the study and did not enroll any participants. Therefore, data is reported only for Treatment Groups 1 and 3.
| Milestone | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Extension Phase: Treatment Group 1: LEN + TAB + ZAB | Extension Phase Treatment Group 3: SBR |
|---|---|---|---|---|
| Started | 56 | 27 | 0 | 0 |
| Completed | 50 | 24 | 0 | 0 |
| Not completed | 6 | 3 | 0 | 0 |
| Withdrew: Still on study | 2 | 1 | 0 | 0 |
| Withdrew: Randomized but never treated | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 |
| Milestone | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Extension Phase: Treatment Group 1: LEN + TAB + ZAB | Extension Phase Treatment Group 3: SBR |
|---|---|---|---|---|
| Started | 0 | 0 | 47 | 24 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 47 | 24 |
| Withdrew: Still on study | 0 | 0 | 47 | 24 |
Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.
| percentage of participants | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm | 1.9 (0.0 to 10.1) | 0.0 (0.0 to 12.8) |
Percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52 was analyzed using US FDA-defined snapshot algorithm, which defines a participant's virologic outcome and included participants a) who had last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 52 analysis window; or b) who did not have on-treatment HIV-1 RNA data in the Week 52 analysis window and i) discontinued study drug prior to or in the Week 52 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 52 analysis window due to adverse event (AE) or death and had last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 52 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Clopper-Pearson exact method was used to calculate the 95% confidence interval (CI) for the outcome measure of each treatment. Percentages were rounded off.
| percentage of participants | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm | 5.7 (1.2 to 15.7) | 0.0 (0.0 to 12.8) |
Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.
| percentage of participants | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm | 96.2 (87.0 to 99.5) | 96.3 (81.0 to 99.9) |
Percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 52 analysis window. The Clopper-Pearson exact method was used to calculate the 95% CI for the outcome measure of each treatment. Percentages were rounded off.
| percentage of participants | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm | 88.7 (77.0 to 95.7) | 92.6 (75.7 to 99.1) |
| cells/µL | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Change From Baseline in Clusters of Differentiation 4 (CD4) + T-cell Counts at Week 26 | 23 ± 143.4 | 74 ± 202.6 |
| cells/μL | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Change From Baseline in CD4+ T-cell Counts at Week 52 | 10 ± 207.8 | 53 ± 123.6 |
Results for this outcome have not been posted.
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
| µg/mL | Randomized Phase Treatment Group 1: LEN + TAB + ZAB |
|---|---|
| TAB | 41.8 ± 22.7 |
| ZAB | 72.0 ± 39.2 |
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
| ng/mL | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB |
|---|---|
| Trough Concentration at Week 26 Predose for LEN | 20.2 ± 10.6 |
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
| ug/mL | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB |
|---|---|
| TAB | 43.1 ± 17.0 |
| ZAB | 56.6 ± 26.8 |
Trough concentration is defined as the concentration of the drug in plasma/serum at the end of the dosing interval.
| ng/mL | Randomized Phase Treatment Group 1: LEN + TAB+ ZAB |
|---|---|
| Trough Concentration at Week 52 Predose for LEN | 25.8 ± 14.2 |
AUC0-tau is defined as the partial area under the concentration versus time curve from time "0" to time "t".
Results for this outcome have not been posted.
t1/2 is defined as the terminal elimination half-life.
Results for this outcome have not been posted.
Cmax is defined as the maximum observed concentration of drug.
Results for this outcome have not been posted.
Cmax is defined as the maximum observed concentration of drug.
Results for this outcome have not been posted.
Tmax is defined as the time (observed time point) of Cmax.
Results for this outcome have not been posted.
Anti-TAB and anti-ZAB antibodies incidence referred to the percentage of participants who have treatment-emergent anti-TAB and anti-ZAB antibodies among all participants evaluable for anti-drug antibody (ADA) incidence.
Results for this outcome have not been posted.
Collected over All-cause Mortality and Adverse events: Up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase Treatment Group 1: LEN + TAB + ZAB | 0/56 (0%) | 1/53 (1.9%) | 43/53 (81.1%) |
| Randomized Phase Treatment Group 3: SBR | 0/27 (0%) | 1/27 (3.7%) | 10/27 (37%) |
| Event | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 1/27 |
| Perineal abscessInfections and infestations | 1/53 | 0/27 |
| Scrotal abscessInfections and infestations | 1/53 | 0/27 |
| Event | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR |
|---|---|---|
| Injection site noduleGeneral disorders | 25/53 | 0/27 |
| Injection site painGeneral disorders | 12/53 | 0/27 |
| Injection site erythemaGeneral disorders | 11/53 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 7/53 | 1/27 |
| Injection site indurationGeneral disorders | 7/53 | 0/27 |
| Upper respiratory tract infectionInfections and infestations | 5/53 | 0/27 |
| Covid-19Infections and infestations | 3/53 | 2/27 |
| ParonychiaInfections and infestations | 0/53 | 2/27 |
| Erectile dysfunctionReproductive system and breast disorders | 0/53 | 2/27 |
| ConstipationGastrointestinal disorders | 3/53 | 0/27 |
The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug (ie, study treatment, including LEN, TAB, ZAB, or continued with their baseline ART regimen).
| Age, Categorical(Participants) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 26 | 78 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| Mean | 44 ± 13.7 | 53 ± 9.6 | 47 ± 13.0 |
| Sex: Female, Male(Participants) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| Female | 8 | 4 | 12 |
| Male | 45 | 23 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 20 |
| Not Hispanic or Latino | 40 | 20 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 8 | 29 |
| White | 28 | 16 | 44 |
| More than one race | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| United States | 48 | 19 | 67 |
| Australia | 2 | 6 | 8 |
| Puerto Rico | 2 | 1 | 3 |
| Canada | 1 | 1 | 2 |
| Clusters of Differentiation 4 (CD4)+ T-cell Counts(cells/µL) | Randomized Phase Treatment Group 1: LEN + TAB + ZAB | Randomized Phase Treatment Group 3: SBR | Total |
|---|---|---|---|
| Mean | 740 ± 239.3 | 764 ± 264.9 | 748 ± 246.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2023 to primary completion in Jul 2024, 13 months.
Results were first posted in Jul 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Teropavimab · Zinlirvimab